Neurocrine Wins FDA Approval For Genetic Disorder Drug

Blockhead12-14

Neurocrine Biosciences (NBIX) won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades. ↑ X How To Buy Stocks: IBD's Four Pillars Of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491538789?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2024/04/Stock-neurocrinebio-02-shutt-150x150.jpg","is_english":true,"pubTime":"2024-12-14 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491538789","market":"sg","top_or_hot":-1,"title":"Neurocrine Wins FDA Approval For Genetic Disorder Drug","media":"Blockhead","content":"<div>\n<p>Neurocrine Biosciences (NBIX) won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: IBD's Four Pillars Of ...</p>\n\n<a href=\"https://www.investors.com/news/technology/neurocrine-biosciences-cah-treatment-crinecerfont/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine Wins FDA Approval For Genetic Disorder Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine Wins FDA Approval For Genetic Disorder Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-14 08:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/neurocrine-biosciences-cah-treatment-crinecerfont/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neurocrine Biosciences (NBIX) won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: IBD's Four Pillars Of ...</p>\n\n<a href=\"https://www.investors.com/news/technology/neurocrine-biosciences-cah-treatment-crinecerfont/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1983299246.USD","symbol_name":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","start_time":0,"source_url":"https://www.investors.com/news/technology/neurocrine-biosciences-cah-treatment-crinecerfont/","article_id":"2491538789","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/04/Stock-neurocrinebio-02-shutt-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491538789","pubTimestamp":1734134447,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Neurocrine Biosciences won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4534":"瑞士信贷持仓","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0882574055.USD":"富达全球健康医疗A ACC","BK4121":"生命科学工具和服务","NBIX":"神经分泌生物科学","BK4559":"巴菲特持仓","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0861579265.USD":"联博低波幅策略股票基金A","ABBV":"艾伯维公司","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","GENE":"基因技术ADR","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4581":"高盛持仓","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H"},"translate_title":"Neurocrine遗传疾病药物获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"NBIX":1,"GENE":1},"content_text":"Neurocrine Biosciences (NBIX) won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: IBD's Four Pillars Of Investing\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow To Buy Stocks: IBD's Four Pillars Of Investing\n\n\n\n\nThe approval of Neurocrine's newest drug, Crenessity, came roughly two weeks ahead of expectations. Crenessity, formerly crinecerfont, is treats congenital adrenal hyperplasia, or CAH, in adults and children as young as 4 years old.\nCAH is characterized by an imbalance between hormones called cortisol and androgens. When the body can't make enough of the cortisol hormone, another hormone known as ACTH climbs. This causes the body to overproduce androgens, or male sex hormones like testosterone.\nFor decades, patients have used glucocorticoids to treat their CAH. But long-term use of these drugs — especially at the high dosages required in CAH — can cause weight gain, cardiovascular issues and bone loss.\nCrenessity will be an important change for patients, said Neurocrine Chief Executive Kyle Gano.\n\"Patients aren't having to make that Sophie's choice anymore between high ACTH, high androgens or high (glucocorticoids) and dealing with the consequences of high-dose (glucocorticoids),\" he told Investor's Business Daily. \"We think this is going to change the standard of care for patients with CAH.\"\nNeurocrine Biosciences: First-In-Class Drugs\nAhead of the approval, Gano said the company expects to launch Crenessity within a week of its approval. He estimates there are 30,000 patients in the U.S. with CAH. They mirror the country's population: roughly a third are adolescents and two-thirds are adults.\nFor children, the earlier they start treatment, the better, Gano said. Parents are particularly motivated to get their children off the glucocorticoid rollercoaster.\nCrenessity will be Neurocrine Biosciences' third drug on the market. The company is best known for its drug Ingrezza, which treats tardive dyskinesia. Neurocrine also licensed to AbbVie (ABBV) the rights to an endometriosis treatment called Orlissa.\n\"All of these medicines, when they were approved were the first in class,\" Gano said. \"We do think that Ingrezza and crinecerfont will change the standard of view for patients, and we're hoping that view, externally, will be one that people take away for Neurocrine. They're all first-in-class medicines that can change the standard of care for patients. And that's really our north star, where we point all our R&D.\"\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nPatterson Launches On $4.1 Billion Takeover. Can It Reinvigorate The Beleaguered Dental Space?\nCandel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug\nIBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks\nLearn How To Time The Market With IBD's ETF Market Strategy\nSee Stocks On The List Of Leaders Near A Buy Point","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491538789"}